TERI SCHWARZ: Open Payments
NPI 1487707972 · METAIRIE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,058 in 65 payments from 10 companies in 2025. Trend: 2023 $2,654 · 2024 $911 · 2025 $1,058
Food & beverage: $1,058
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $229 |
| Alkermes, Inc. | 10 | $188 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $149 |
| Teva Pharmaceuticals USA, Inc. | 8 | $135 |
| Neurocrine BioSciences, Inc. | 5 | $98 |
| Noven Therapeutics, LLC | 4 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| ABBVIE INC. | 3 | $67 |
| E.R. Squibb & Sons, L.L.C. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $22 |
Products named: REXULTI, ARISTADA, CAPLYTA, AUSTEDO XR, INGREZZA, Xelstrym, FANAPT, VRAYLAR.
Industry payments across LA — which companies pay providers there.
